Anti-tuberculosis agent combination

This page covers all Anti-tuberculosis agent combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Multiple: DNA gyrase (moxifloxacin), RNA polymerase (rifampicin), mycolic acid synthesis (isoniazid, pyrazinamide), arabinosyl transferase (ethambutol).

Targets

Multiple: DNA gyrase (moxifloxacin), RNA polymerase (rifampicin), mycolic acid synthesis (isoniazid, pyrazinamide), arabinosyl transferase (ethambutol)

Phase 3 pipeline (1)

• Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin · Global Alliance for TB Drug Development · Infectious Disease
  This is a fixed-dose combination of five anti-tuberculosis agents that work through multiple mechanisms to inhibit bacterial cell wall synthesis, protein synthesis, and DNA replication in Mycobacterium tuberculosis.

Patent intelligence

• tuberculosis agent combination patent landscape — aggregated cliff calendar, attackable patents, originator estates